Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
复制标题
DOI:
10.1038/clpt.2012.3
复制
发表时间:
2012-06
影响因子:
6.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Nonsteroidal anti-inflammatory drugs (NSAIDs) elevate cardiovascular risk by disrupting cyclooxygenase-2 (COX-2)-dependent biosynthesis of prostacyclin (PGI2). CG100649 is a novel NSAID proposed to inhibit both COX-2 and carbonic anhydrase (CA)-I/-II. We compared its impact on prostanoid biosynthesis with that of celecoxib, an NSAID purposefully designed to selectively inhibit COX-2. In a controlled, double-blind randomized trial, single oral doses of 2 or 8 mg CG100649, 200 mg celecoxib, or placebo were well tolerated by healthy volunteers (n = 23). Both CG100649 and celecoxib had the effect of depressing urinary excretion of 2,3-dinor-6-keto-PGF1α (PGI-M); the effect of CG100649 was dose-dependent and more sustained (up to 240 h after the dose) than that of celecoxib. Neither CG100649 nor celecoxib significantly inhibited COX-1-dependent prostanoid formation. CA inhibition was not detected after administration of CG100649, despite its partitioning asymmetrically into erythrocytes. CG100649 and celecoxib are both relatively selective inhibitors of COX-2, but they differ in duration of action. Whether they have similar impact on cardiovascular events remains to be determined.
登录
查看更多内容
DOI:
10.1111/j.1532-5415.1996.tb01437.x
发表时间:
1996-05-01
影响因子:
6.3
作者:
Kahn, S;Frishman, WH;Aronson, M
通讯作者:
Aronson, M
影响因子:
13.8
作者:
FitzGerald, Garret A.
通讯作者:
FitzGerald, Garret A.
DOI:
10.1016/j.ejpb.2009.05.009
发表时间:
2009-09-01
影响因子:
4.9
作者:
Shono, Yasushi;Jantratid, Ekarat;Dressman, Jennifer B.
通讯作者:
Dressman, Jennifer B.
影响因子:
10.4
作者:
Yu, Y.;Ricciotti, E.;Fitzgerald, G. A.
通讯作者:
Fitzgerald, G. A.
影响因子:
29.4
作者:
Fries, S;Grosser, T;Fitzgerald, GA
通讯作者:
Fitzgerald, GA